Mast cell stabilization is the single most repeated mechanistic claim made for palmitoylethanolamide (PEA). It appears in nearly every explanation of how the compound is supposed to work, including on this site. Allergic rhinitis is the condition where that mechanism should be easiest to demonstrate, because the whole disorder is driven by mast cells releasing histamine in response to an allergen.
So it matters that when somebody finally ran the trial, PEA did not beat placebo on the symptom score it was designed to move.
That result is worth reading carefully rather than skipping past. The trial was not a failure in the sense of finding nothing. It found changes in inflammatory biology, and it found a difference in one subgroup. What it did not find was the headline most supplement pages would want.
Key Takeaways
- In a double-blind, randomized, placebo-controlled trial of 108 people with seasonal allergic rhinitis, PEA 350 mg daily for two weeks produced no significant difference in nasal symptom scores compared with placebo [1].
- A sub-group analysis of participants who scored above four on the symptom scale at baseline did show a significant reduction with PEA [1]. Sub-group findings generate hypotheses, they do not confirm them.
- Blood work in the PEA group showed significant decreases from baseline in histamine, IL-4, IL-8, IL-10 and TNF-alpha, while the placebo group showed a reduction only in IL-4 [1].
- Only 36 of the 101 completers had full blood sets taken, because COVID-19 disrupted collection [1]. The biomarker result rests on roughly a third of the trial.
- The product tested was Levagen+, a commercially branded PEA ingredient, in a study authored by researchers connected to the ingredient supplier [1]. The same ingredient did hit its endpoints in a separate respiratory infection trial [2].
Why Allergy Is the Test Case for the Mast Cell Claim
Allergic rhinitis is an inflammatory, symptomatic disorder driven by antigen-specific immunoglobulin E responses to allergens, and standard treatment uses corticosteroids and antihistamines to blunt inflammation and histamine release [1]. PEA has been proposed as an alternative on the grounds that it downregulates mast cell activation and increases synthesis of the endocannabinoid 2-arachidonoylglycerol, which would in turn reduce histamine and the resulting symptoms [1].
That is a clean, falsifiable prediction. If PEA calms mast cells in a living person at a dose people actually take, hay fever symptoms should fall. Most conditions PEA is studied in are messier than this. Chronic pain has enormous placebo responses and subjective endpoints. Allergy has a seasonal trigger, a validated symptom instrument, and measurable inflammatory chemistry in the blood.
The compound itself is well characterised at the receptor level. PEA exerts most of its biological effects through activation of PPAR-alpha, with additional PPAR-alpha-independent pathways involving TRPV1 and GPR55 [3]. Reviews list allergy among its documented application areas alongside immunity, pain modulation, joint health and sleep [4]. The question was never whether the mechanism is plausible. It was whether it produces a result you can feel.
What the Trial Did
The study was a double-blind, randomised, placebo-controlled clinical trial in which 108 participants presenting with seasonal allergic rhinitis were supplemented with either 350 mg of PEA as Levagen+ or a matched placebo daily for two weeks [1]. Symptom scores were recorded using the reflective total nasal symptom score, or rTNSS, twice daily in the morning and evening across the full fourteen days, with blood drawn at baseline and at week two [1].
101 participants completed the study, and there were no baseline differences between the groups [1]. That is a reasonably sized trial by supplement standards, with a validated instrument, twice-daily capture rather than a single recall at the end, and a laboratory arm attached.
The Primary Result: No Significant Difference
The trial reported, in plain terms, that no significant difference was seen between groups for allergy symptom scores throughout the fourteen days of treatment [1].
That is the primary outcome. It is the number the study was built to produce, the comparison the randomization exists to protect, and it came back null. Any page that tells you PEA is a proven treatment for hay fever is not describing this trial.
The reason to lead with that rather than bury it is practical. Somebody with streaming eyes in April is deciding whether to spend money on a two-week supply. The honest answer from the best-designed study available is that across an unselected group of seasonal allergy sufferers, it did not outperform a dummy capsule on how their nose felt.
The Sub-Group That Did Respond
A sub-group analysis of participants scoring over four on the total rTNSS at baseline, meaning the mild-to-moderate rather than mild end of the population, showed that PEA significantly reduced scores compared with the placebo group [1].
This is the most interesting number in the paper and also the one most likely to be misused. A sub-group analysis carved out after the fact is not protected by the original randomization in the same way the primary endpoint is. With enough slices of a dataset, some slice will show a difference by chance. The finding is a hypothesis worth testing in a trial designed around it from the start, recruiting only people above that symptom threshold. Until somebody runs that trial, it is a lead, not a result.
It is, though, a biologically coherent lead. Floor effects are a real problem in symptom trials. People who barely have symptoms cannot improve much, and including them dilutes any true effect. That is exactly the pattern this sub-group finding would produce if PEA genuinely works in people with meaningful symptoms.
The Blood Work, and Its Limits
The pathology results showed a significant difference in change from baseline between groups [1]. The PEA group had significant decreases from baseline in histamine, IL-4, IL-8, IL-10 and TNF-alpha, while the placebo group showed a reduction only in IL-4 [1].
Histamine falling is the specific prediction the mast cell hypothesis makes, and it fell. That is not nothing. It suggests the compound is doing something measurable in allergic inflammation even when the symptom questionnaire does not register it.
The limit is sample size. Only 36 participants had full sets of blood taken, because of COVID-19 disruption [1]. That is roughly a third of the completers, and it was not a planned subset chosen for any scientific reason. Inflammatory markers are variable between people, so a 36-person biomarker comparison is fragile. Read it as consistent with the mechanism rather than as proof of it.
The Same Ingredient, a Different Answer
The most useful context for this trial is the one that ran alongside it. The same branded PEA ingredient was tested in a double-blind, randomised, placebo-controlled trial of 426 participants taking 300 mg twice daily for twelve weeks, aimed at upper respiratory tract infections [2]. That study reported fewer infection episodes in the PEA group, 39 versus 64, and significant reductions in median severity scores for scratchy throat and cough [2].
A third trial applied a topical PEA formulation to eczema in 72 people over four weeks and reported significant reductions in redness, dryness and total symptom score against a comparator moisturiser [5].
So the same ingredient, from the same research group, produced a null primary result in allergy, a positive result in respiratory infection, and a positive result in topical eczema. That pattern argues against dismissing the compound outright and equally against believing every claim made for it. It is what a real research programme looks like: some endpoints move, some do not, and the honest reader has to hold both.
What This Means If You Have Hay Fever
The practical reading is narrow and specific. There is no randomized evidence that PEA relieves seasonal nasal allergy symptoms across a general allergy population, because the trial designed to show that came back null [1]. There is a hypothesis-grade signal that people with more than mild symptoms may respond, and a small biomarker dataset consistent with mast cell effects [1].
PEA is very well tolerated in humans, which is why the compound keeps being tested at all [3], and reviews describe it as devoid of side effects in animals and humans [4]. Tolerability is not efficacy, but it does change the risk calculus for a two-week trial of something on yourself. What it should not do is displace treatment that has been shown to work. Nothing in this literature supports stopping an antihistamine or a prescribed corticosteroid spray in favour of a supplement.
One practical detail carries over from the pharmacology. PEA has poor oral bioavailability in its raw form, an obstacle that formulation work has been aimed at overcoming [4], and the pharmacokinetics remain poorly characterised, with real gaps in what is known about bioavailability, tissue distribution and excretion [3]. If you are comparing products, the form matters, which is why this site covers micronized and ultramicronized preparations separately.
Frequently Asked Questions
Does PEA work for hay fever?
The one randomized placebo-controlled trial found no significant difference in nasal symptom scores between PEA and placebo over fourteen days [1]. A sub-group with higher baseline symptoms did improve significantly, but that analysis was not the trial’s primary endpoint and needs a purpose-built study to confirm.
What dose was used in the allergy trial?
350 mg of PEA daily, as the branded Levagen+ ingredient, taken for two weeks during seasonal allergy symptoms [1]. This is lower than the 600 mg twice-daily regimens used in several pain trials covered elsewhere on this site.
Did PEA actually lower histamine?
In the subset of 36 participants who had full blood work, the PEA group showed a significant decrease from baseline in histamine along with IL-4, IL-8, IL-10 and TNF-alpha, while placebo moved only IL-4 [1]. The subset was small and was determined by COVID-19 disruption rather than by design.
Can I take PEA alongside an antihistamine?
This trial did not test that combination, and no interaction study addresses it. PEA is generally well tolerated [3], but a supplement with a null primary result is not a reason to alter medication that works for you. Any change to an allergy regimen belongs with the prescriber.
Why do supplement pages say PEA is proven for allergies?
Because the trial produced quotable positives in a sub-group and in blood markers, and its abstract concludes that the ingredient can alleviate symptoms. Read one sentence earlier and the primary comparison was null [1]. Both statements are in the same paper.
References
- Briskey D, Ebelt P, Rao A. The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis: A Double-Blind Placebo-Controlled Trial. Nutrients (2023). PMID 38068797
- Rao A, Skinner J, Briskey D. The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection: A Double Blind, Randomised, Placebo-Controlled Trial. Nutrients (2023). PMID 37892528
- Rankin L, Fowler CJ. The Basal Pharmacology of Palmitoylethanolamide. Int J Mol Sci (2020). PMID 33114698
- Clayton P, Hill M, Bogoda N, et al. Palmitoylethanolamide: A Natural Compound for Health Management. Int J Mol Sci (2021). PMID 34069940
- Rao A, Moussa AA, Erickson M, Briskey D. Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial. Skin Pharmacol Physiol (2023). PMID 38408443
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
